Patents by Inventor Krishnakumar Ranganathan

Krishnakumar Ranganathan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230099078
    Abstract: A method for preparing AMG 416, or a pharmaceutically acceptable salt thereof, is provided.
    Type: Application
    Filed: June 28, 2022
    Publication date: March 30, 2023
    Inventors: Jeroen BEZEMER, Ying CHEN, Richard CROCKETT, Kevin CROSSLEY, Sheng CUI, Liang HUANG, Sian JONES, Asher LOWER, Krishnakumar RANGANATHAN
  • Patent number: 11377474
    Abstract: A method for preparing AMG 416, or a pharmaceutically acceptable salt thereof, is provided.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: July 5, 2022
    Assignee: AMGEN INC.
    Inventors: Jeroen Bezemer, Ying Chen, Richard Crockett, Kevin Crossley, Sheng Cui, Liang Huang, Sian Jones, Asher Lower, Krishnakumar Ranganathan
  • Patent number: 10858389
    Abstract: The instant disclosure is directed to solution phase fragment coupling methods for preparing etelcalcetide and its pharmaceutically acceptable salts.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: December 8, 2020
    Assignee: Amgen Inc.
    Inventors: Sheng Cui, Krishnakumar Ranganathan, Richard Crockett, Ying Chen, Aleksander Swietlow, Kevin Crossley, Yun Shi, Karel Decroos, Etienne Moniotte
  • Publication number: 20190352336
    Abstract: A method for preparing AMG 416, or a pharmaceutically acceptable salt thereof, is provided.
    Type: Application
    Filed: August 5, 2019
    Publication date: November 21, 2019
    Inventors: Jeroen BEZEMER, Ying CHEN, Richard CROCKETT, Kevin CROSSLEY, Sheng CUI, Liang HUANG, Sian JONES, Asher LOWER, Krishnakumar RANGANATHAN
  • Patent number: 10407464
    Abstract: A method for preparing AMG 416, or a pharmaceutically acceptable salt thereof, is provided. AMG 416 is a synthetic, eight amino-acid selective peptide agonist of the calcium sensing receptor. It is being developed as an intravenous treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients with chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: September 10, 2019
    Assignee: Amgen Inc.
    Inventors: Jeroen Bezemer, Ying Chen, Richard Crockett, Kevin Crossley, Sheng Cui, Liang Huang, Sian Jones, Asher Lower, Krishnakumar Ranganathan
  • Publication number: 20180079777
    Abstract: The instant disclosure is directed to solution phase fragment coupling methods for preparing etelcalcetide and its pharmaceutically acceptable salts.
    Type: Application
    Filed: March 25, 2016
    Publication date: March 22, 2018
    Inventors: Sheng Cui, Krishnakumar Ranganathan, Richard Crockett, Ying Chen, Aleksander Swietlow, Kevin Crossley, Yun Shi, Karel Decroos, Etienne Moniotte
  • Publication number: 20170190739
    Abstract: A method for preparing AMG 416, or a pharmaceutically acceptable salt thereof, is provided. AMG 416 is a synthetic, eight amino-acid selective peptide agonist of the calcium sensing receptor. It is being developed as an intravenous treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients with chronic kidney disease—mineral and bone disorder (CKD-MBD).
    Type: Application
    Filed: April 3, 2015
    Publication date: July 6, 2017
    Inventors: Jeroen BEZEMER, Ying CHEN, Richard CROCKETT, Kevin CROSSLEY, Sheng CUI, Liang HUANG, Sian JONES, Asher LOWER, Krishnakumar RANGANATHAN
  • Patent number: 8754192
    Abstract: The present invention provides isolated homogeneous polyfunctionalized proteins (e.g., erythropoietin), isolated glycopeptides, and a method for preparing polyfunctionalized peptides and/or proteins via cysteine-free native chemical ligation. In certain embodiments, the invention provides an isolated homogeneous polyfunctionalized protein having the structure (I). In certain other embodiments, the invention provides an isolated glycopeptide having Formula (II). In certain other embodiments, the inventive method is a method for preparing a polyfunctionalized peptide comprising a peptidic backbone made up of four or more amino acids, wherein two or more non-adjacent amino acids are independently substituted with a moiety having the structure (III) -LH. wherein A and L1 are as defined herein.
    Type: Grant
    Filed: April 11, 2007
    Date of Patent: June 17, 2014
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Samuel J. Danishefsky, J. David Warren, Jiehao Chen, Bin Wu, Gong Chen, Qian Wan, Zhongping Tan, Cindy Kan, Yu Yuan, Zihao Hua, Krishnakumar Ranganathan, John D. Trzupek
  • Publication number: 20100081786
    Abstract: The present invention provides isolated homogeneous polyfunctionalized proteins (e.g., erythropoietin), isolated glycopeptides, and a method for preparing polyfunctionalized peptides and/or proteins via cysteine-free native chemical ligation. In certain embodiments, the invention provides an isolated homogeneous polyfunctionalized protein having the structure (I). In certain other embodiments, the invention provides an isolated glycopeptide having Formula (II). In certain other embodiments, the inventive method is a method for preparing a polyfunctionalized peptide comprising a peptidic backbone made up of four or more amino acids, wherein two or more non-adjacent amino acids are independently substituted with a moiety having the structure (III)-LH. wherein A and L1 are as defined herein.
    Type: Application
    Filed: April 11, 2007
    Publication date: April 1, 2010
    Inventors: Samuel J. Danishefsky, J. David Warren, Jiehao Chen, Bin Wu, Gong Chen, Qian Wan, Zhongping Tan, Cindy Kan, Yu Yuan, Zihao Hua, Krishnakumar Ranganathan, John D. Trzupek